Monte Rosa Therapeutics Statistics
Total Valuation
GLUE has a market cap or net worth of $1.26 billion. The enterprise value is $677.82 million.
| Market Cap | 1.26B |
| Enterprise Value | 677.82M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GLUE has 85.31 million shares outstanding. The number of shares has increased by 11.91% in one year.
| Current Share Class | 85.31M |
| Shares Outstanding | 85.31M |
| Shares Change (YoY) | +11.91% |
| Shares Change (QoQ) | +1.60% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 80.11% |
| Float | 54.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 44.19 |
| Forward PS | 26.28 |
| PB Ratio | 2.76 |
| P/TBV Ratio | 2.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.58, with a Debt / Equity ratio of 0.08.
| Current Ratio | 10.58 |
| Quick Ratio | 10.49 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.66% and return on invested capital (ROIC) is -27.24%.
| Return on Equity (ROE) | -42.66% |
| Return on Assets (ROA) | -21.63% |
| Return on Invested Capital (ROIC) | -27.24% |
| Return on Capital Employed (ROCE) | -28.80% |
| Weighted Average Cost of Capital (WACC) | 12.28% |
| Revenue Per Employee | $166,052 |
| Profits Per Employee | -$931,306 |
| Employee Count | 173 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.86M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +235.91% in the last 52 weeks. The beta is 1.53, so GLUE's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | +235.91% |
| 50-Day Moving Average | 20.03 |
| 200-Day Moving Average | 18.48 |
| Relative Strength Index (RSI) | 31.32 |
| Average Volume (20 Days) | 1,523,232 |
Short Selling Information
The latest short interest is 16.46 million, so 19.29% of the outstanding shares have been sold short.
| Short Interest | 16.46M |
| Short Previous Month | 17.20M |
| Short % of Shares Out | 19.29% |
| Short % of Float | 30.21% |
| Short Ratio (days to cover) | 10.88 |
Income Statement
In the last 12 months, GLUE had revenue of $28.73 million and -$161.12 million in losses. Loss per share was -$1.74.
| Revenue | 28.73M |
| Gross Profit | -133.63M |
| Operating Income | -181.85M |
| Pretax Income | -163.97M |
| Net Income | -161.12M |
| EBITDA | -173.73M |
| EBIT | -181.85M |
| Loss Per Share | -$1.74 |
Balance Sheet
The company has $621.10 million in cash and $37.99 million in debt, with a net cash position of $583.12 million or $6.84 per share.
| Cash & Cash Equivalents | 621.10M |
| Total Debt | 37.99M |
| Net Cash | 583.12M |
| Net Cash Per Share | $6.84 |
| Equity (Book Value) | 487.28M |
| Book Value Per Share | 5.72 |
| Working Capital | 571.75M |
Cash Flow
In the last 12 months, operating cash flow was -$24.07 million and capital expenditures -$8.01 million, giving a free cash flow of -$32.08 million.
| Operating Cash Flow | -24.07M |
| Capital Expenditures | -8.01M |
| Depreciation & Amortization | 8.13M |
| Net Borrowing | n/a |
| Free Cash Flow | -32.08M |
| FCF Per Share | -$0.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | -633.04% |
| Pretax Margin | -570.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.91% |
| Shareholder Yield | -11.91% |
| Earnings Yield | -12.69% |
| FCF Yield | -2.53% |
Analyst Forecast
The average price target for GLUE is $28.50, which is 92.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.50 |
| Price Target Difference | 92.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -6.25% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GLUE has an Altman Z-Score of 2.09 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.09 |
| Piotroski F-Score | 2 |